Literature DB >> 29608764

mTOR inhibition in glioblastoma: requiem for a dream?

Sam Babak1, Warren P Mason1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29608764      PMCID： PMC5892149          DOI： 10.1093/neuonc/noy034

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Authors:  Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla Ballman; J Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

2.  A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.

Authors:  Prakash Chinnaiyan; Minhee Won; Patrick Y Wen; Amyn M Rojiani; Maria Werner-Wasik; Helen A Shih; Lynn S Ashby; Hsiang-Hsuan Michael Yu; Volker W Stieber; Shawn C Malone; John B Fiveash; Nimish A Mohile; Manmeet S Ahluwalia; Merideth M Wendland; Philip J Stella; Andrew Y Kee; Minesh P Mehta
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

3.  Gene expression profiling and genetic markers in glioblastoma survival.

Authors:  Jeremy N Rich; Christopher Hans; Beatrix Jones; Edwin S Iversen; Roger E McLendon; B K Ahmed Rasheed; Adrian Dobra; Holly K Dressman; Darell D Bigner; Joseph R Nevins; Mike West
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

4.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Authors:  D D Sarbassov; Siraj M Ali; Do-Hyung Kim; David A Guertin; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Curr Biol       Date:  2004-07-27       Impact factor: 10.834

Review 5.  Primary brain tumours in adults.

Authors:  Anthony Behin; Khe Hoang-Xuan; Antoine F Carpentier; Jean-Yves Delattre
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

6.  A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

Authors:  Teri N Kreisl; Andrew B Lassman; Paul S Mischel; Neal Rosen; Howard I Scher; Julie Teruya-Feldstein; David Shaffer; Eric Lis; Lauren E Abrey
Journal:  J Neurooncol       Date:  2008-11-19       Impact factor: 4.130

7.  RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

Authors:  Prakash Chinnaiyan; Minhee Won; Patrick Y Wen; Amyn M Rojiani; Merideth Wendland; Thomas A Dipetrillo; Benjamin W Corn; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-05-29       Impact factor: 7.038

8.  mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

Authors:  Do-Hyung Kim; D D Sarbassov; Siraj M Ali; Jessie E King; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

9.  Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.

Authors:  A P Mander; S G Thompson
Journal:  Contemp Clin Trials       Date:  2010-08-01       Impact factor: 2.226
  9 in total
  8 in total

1.  Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma.

Authors:  Miriam Ratliff; Hichul Kim; Hao Qi; Minsung Kim; Bosung Ku; Daniel Dominguez Azorin; David Hausmann; Rajiv K Khajuria; Areeba Patel; Elena Maier; Loic Cousin; Arnaud Ogier; Felix Sahm; Nima Etminan; Lukas Bunse; Frank Winkler; Victoria El-Khoury; Michael Platten; Yong-Jun Kwon
Journal:  Int J Mol Sci       Date:  2022-06-12       Impact factor: 6.208

2.  Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma.

Authors:  Michael W Ronellenfitsch; Pia S Zeiner; Michel Mittelbronn; Hans Urban; Torsten Pietsch; Dirk Reuter; Christian Senft; Joachim P Steinbach; Manfred Westphal; Patrick N Harter
Journal:  Acta Neuropathol Commun       Date:  2018-08-21       Impact factor: 7.801

3.  Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells.

Authors:  Gábor Petővári; Zoltán Hujber; Ildikó Krencz; Titanilla Dankó; Noémi Nagy; Fanni Tóth; Regina Raffay; Katalin Mészáros; Hajnalka Rajnai; Enikő Vetlényi; Krisztina Takács-Vellai; András Jeney; Anna Sebestyén
Journal:  Cancer Cell Int       Date:  2018-12-19       Impact factor: 5.722

4.  Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment.

Authors:  Dennis Heinzen; Iris Divé; Nadja I Lorenz; Anna-Luisa Luger; Joachim P Steinbach; Michael W Ronellenfitsch
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 6.208

Review 5.  Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).

Authors:  Marsel Khabibov; Airat Garifullin; Yanis Boumber; Karam Khaddour; Firat Khamitov; Manuel Fernandez; Larisa Khalikova; Natalia Kuznetsova; Oleg Kit; Leonid Kharin
Journal:  Int J Oncol       Date:  2022-04-21       Impact factor: 5.884

Review 6.  Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future.

Authors:  Wenda Huang; Zhaonian Hao; Feng Mao; Dongsheng Guo
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

Review 7.  Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update.

Authors:  Mayra Colardo; Marco Segatto; Sabrina Di Bartolomeo
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

8.  Autophagy Modulators Profoundly Alter the Astrocyte Cellular Proteome.

Authors:  Affan Ali Sher; Ang Gao; Kevin M Coombs
Journal:  Cells       Date:  2020-03-26       Impact factor: 6.600
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.